275MO Overall efficacy outcomes of nivolumab plus ipilimumab by occurrence of immune-mediated adverse events (IMAEs) and additional safety from Asian patients in CheckMate 9DW — T. Yau (2025) | RDL Network
275MO Overall efficacy outcomes of nivolumab plus ipilimumab by occurrence of immune-mediated adverse events (IMAEs) and additional safety from Asian patients in CheckMate 9DW
George Lau, Ann‐Lii Cheng, Bruno Sangro, Masatoshi Kudo, Robin Kate Kelley, Won Young Tak, Antonio Gasbarrini, María Reig, Ho Yeong Lim, David Tougeron, Enrico N. De Toni, Vincent C. Tam, Kabir Mody, Jun Gong, Carrie L. McCoy, Charu Gupta, Mallory Makowsky, Alejandra Negro, Ghassan K. Abou‐Alfa
Thomas Yau, Chih‐Hung Hsu, Yoon‐Koo Kang, T. Kim, Ming‐Mo Hou, Ho Yeong Lim, Yee Chao, Y. Kim, Masafumi Ikeda, Su Pin Choo, Jaclyn Neely, Yun Shen, Marina Tschaika, Masatoshi Kudo
Thomas Yau, Yoon‐Koo Kang, Tae‐You Kim, Anthony B. El-Khoueiry, Armando Santoro, Bruno Sangro, Ignacio Melero, Masatoshi Kudo, Ming-Mo Hou, Ana Matilla, Francesco Tovoli, Jennifer J. Knox, Aiwu Ruth He, Bassel F. El‐Rayes, Mirelis Acosta-Rivera, Ho-Yeong Lim, Jaclyn Neely, Yun Shen, Tami Wisniewski, Jeffrey Anderson, Chiun Hsu
Discussion(0)
No comments yet. Be the first to comment.